CALC

Insider Trades

Name	Value	Action	Price	Current Price
Wilson Robert NDirector $200k53.3k shares BuyNov 1, 2024 $3.75 --
Roberts Eric WDirector, 10 Percent Owner, Officer: CHIEF BUSINESS OFFICER $200k53.3k shares BuyNov 1, 2024 $3.75 --
Leheny A. RachelDirector, 10 Percent Owner, Officer: CHIEF EXECUTIVE OFFICER $75k20k shares BuyNov 1, 2024 $3.75 --
Middleton Fred ADirector, 10 Percent Owner: $3.3k877 shares BuyNov 1, 2024 $3.75 --
Middleton Fred ADirector, 10 Percent Owner: $75k20k shares BuyNov 1, 2024 $3.75 --
Middleton Fred ADirector, 10 Percent Owner: $326k86.9k shares BuyNov 1, 2024 $3.75 --

News

prnewswire.comCalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updatesprnewswire.comMay 12

Trade CALC

About CalciMedica, Inc.

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

CEO: A. Rachel Leheny
IPO Date: Jun 14, 2023

Market Data

Open: $0.86
High: $0.86
Low: $0.7502
Volume: 105.5K
Avg Volume: 226.1K
52W High: $7.20
52W Low: $0.461

Valuation

Market Cap: $12M
Enterprise Value: $3.8M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-21M
Revenue: $0
Net Income: $-30M
Cash: $12M
Debt: $9.7M

Events

EarningsAug 11

EPS est. -0.28